SU2C-PCF Dream Team: Precision Therapy of Advanced Prostate Cancer (2012-2016)

You are here

Funded by American Association for Cancer Research (AACR).

Funding Years: 2012-2016. 

Specific Research Goals:

  • Establish a multi-institutional infrastructure incorporating five leading prostate cancer clinical sites and two sequencing and computational analysis sites that will coordinate sample and data acquisition and analysis;
  • Systematically evaluate biopsies from 500 patients with metastatic CRPC, using next-generation sequencing technology, to identify biomarkers of response to treatment; 
  • Conduct parallel preclinical studies to elucidate resistance and response mechanisms to treatment using panels of CRPC xenografts (mouse “avatars”); Conduct clinical trials of novel combinations targeting androgen receptor (AR) and/or PTEN pathway; and
  • Identify molecular determinants of response to PARP inhibitors, as well as molecular determinants of sensitivity and acquired resistance to abiraterone and MDV3100 in patients.

Click here for more details.

PI(s): Arul M. Chinnaiyan

Co-I(s): Scott Kim, Lakshmi Kunju, Maha Hussain, Sameek Roychowdhury, Felix Feng, Scott Roberts, Kenneth Pienta, Rohit Mehra, Raymond De Vries, Dan Robinson, Scott Tomlins